SCHEMBL25101407

SCHEMBL25101407

CC(C)C(=O)NCC1CCCN(CCCN2CCN(C(C)C)CC2)CCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FPR3 P25089 2/20 0.42
FPR2 P25090 2/20 0.42
HRH3 Q9Y5N1 3/20 0.40
DPP4 P27487 1/20 0.40
PREP P48147 1/20 0.40
FAP Q12884 1/20 0.40
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
HTR4 Q13639 2/20 0.38
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
MAOB P27338 2/20 0.38
SIGMAR1 Q99720 1/20 0.37
ALDH1A1 P00352 2/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
RAD52 P43351 1/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 1/20 0.36
EPHX1 P07099 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22302357 0.92 HTR4 (0.43) HRH3HTR4DRD2DRD4MAOB
SCHEMBL26330243 0.87 HTR4 (0.41) HRH3DPP4PREPFAPMEN1
SCHEMBL22306149 0.82 HTR4 (0.37) FPR3FPR2DPP4PREPFAP
SCHEMBL26141947 0.81 DRD2 (0.36) FPR3FPR2HTR4DRD2DRD4
SCHEMBL25101473 0.81 DRD2 (0.36) FPR3FPR2HRH3HTR4DRD2
SCHEMBL23709475 0.80 HTR4 (0.46) HRH3DPP4PREPFAPMEN1
SCHEMBL25089654 0.80 EPHX1 (0.46) HTR4DRD2DRD4TP53SMN1; SMN2
SCHEMBL24941968 0.80 KCNH2 (0.39) HRH3DPP4PREPFAPHTR4
SCHEMBL18908753 0.78 SMN1; SMN2 (0.55) DRD2DRD4MAOBALDH1A1TP53
SCHEMBL22302242 0.77 NAMPT (0.38) FPR3FPR2DRD2DRD4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067642-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2024-02-29 US disclosed
US-20230331722-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-10-19 US disclosed
US-20230066136-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230066136-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 FPR3 4250/4885FPR2 4487/4885HRH3 2014/4885
US-20230331722-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 FPR3 4250/4885FPR2 4487/4885HRH3 2014/4885
US-20240067642-A1 COMPOUNDS AND USES THEREOF VHL, TFEB, BECN1 FPR3 4250/4885FPR2 4487/4885HRH3 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.